

August 09, 2024

To,
National Stock Exchange of India Ltd.
Exchange Plaza,
Bandra-Kurla Complex,
Bandra (East), Mumbai-400 051
Symbol: JLHL

To,
BSE Limited
P.J. Towers,
25th Floor, Dalal Street, Fort
Mumbai 400 001
Code: 543980

Subject: Outcome of the Board Meeting held on Friday, August 09, 2024

Dear Sir/Madam,

In furtherance to our intimation dated August 05, 2024, this is to inform you that pursuant to Regulations 30, 33, and Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the Company at its Meeting held today, i.e., August 09, 2024, has inter-alia:

1. Considered and approved the Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2024, along with the Limited Review Report.

A copy of the said Results along with the Limited Review Report issued by the Statutory Auditors of the Company is enclosed herewith as **Annexure – I**.

2. Considered and approved the appointment of M/s. Varma & Varma, Chartered Accountants as Internal Auditor of the Company for the financial year 2024-25.

Brief Profile of M/s. Varma & Varma, in terms of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations') and SEBI Circular No. SEBI/HO/CFD/CFDPoD-1/P/CIR/2023/123 dated July 13, 2023 ("SEBI Circular"), is enclosed herewith as **Annexure – II**.

3. Considered and approved the appointment of Mr. Amar Manjrekar (DIN: 00463989) as an Additional Director in the capacity of Non-Executive Independent Director of the Company for a period of 5 (five) years, subject to the approval of shareholders of the company.

Brief Profile of Mr. Amar Manjrekar, in terms of SEBI Listing Regulations and with SEBI Circular is enclosed herewith as **Annexure-III**.

The same will be available on the website of the Company at www.jupiterhospital.com.

The Board Meeting commenced at 03:00 P.M. and concluded at 3.40 P.M.

You are requested to kindly take the afore-mentioned on record and oblige.

Thanking You,

For JUPITER LIFE LINE HOSPITALS LIMITED

Suma Upparatti
Company Secretary & Compliance Officer

Annexure 1

Independent Auditor's Review Report on standalone unaudited quarterly financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

TO THE BOARD OF DIRECTORS OF JUPITER LIFE LINE HOSPITALS LIMITED

We have reviewed the accompanying statement of standalone unaudited financial results of Jupiter Life Line Hospitals Limited for the quarter ended 30th June 2024. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. The statement has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") [prescribed u/s 133 of the Companies Act 2013, and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of standalone unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Aswin P. Malde & Co.
Chartered Accountants
FRN 100725W

Aswin P. Malde
Proprietor
M.No.032662
9th August, 2024, Mumbai
UDIN : 24032662BKAKAE5532

JUPITER LIFE LINE HOSPITALS LIMITED

CIN: U85100MH2002PLC137908

STATEMENT OF UNAUDITED STADALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2024

(Rs in Millions)

Particulars	Unaudited	Unaudited	Unaudited	Audited
	quarter ended	quarter ended	quarter ended	year ended
	30th June	31st March	30th June	31st March
	2024	2024	2023	2024
Revenue from Opertations	2,394.06	2,453.13	2,078.73	9,106.33
Other income	82.41	87.41	67.92	296.28
TOTAL INCOME	2,476.47	2,540.54	2,146.65	9,402.61
EXPENSES				
Purchases of Stock-in-Trade	435.81	447.94	366.46	1,599.96
Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	(27.71)	2.19	(12.54)	(12.71)
Employee benefits expense	425.02	425.32	376.15	1,586.09
Finance costs	9.45	9.25	82.09	186.55
Depreciation and amortisation expense	79.84	74.69	77.54	305.23
Professional Fees	591.29	583.93	503.85	2,209.65
Other expenses	412.87	429.90	333.45	1,489.63
TOTAL EXPENSES	1,926.57	1,973.22	1,727.00	7,364.40
Profit before exceptional items and tax	549.90	567.32	419.65	2,038.21
Exceptional items [net credit/ (charge)]	-	22.82	(13.60)	-
Profit before tax	549.90	590.14	406.05	2,038.21
Tax expenses	143.40	158.67	101.65	518.68
Current tax	145.91	159.27	102.08	518.87
Adjustments in respect of current income tax of previous year	-	3.27	-	1.52
MAT Credit Entitlement	-	-	-	-
Deferred tax credit/(charge)	(2.51)	(3.87)	(0.43)	(1.71)
PROFIT FOR THE PERIOD (A)	406.50	431.47	304.40	1,519.53
OTHER COMPREHENSIVE INCOME				
Items that will not be reclassified subsequently to profit or loss				
Remeasurements of the net defined benefit plans	-	(8.52)	-	(8.52)
Others	-	-	21.25	21.55
OTHER COMPREHENSIVE INCOME FOR THE PERIOD (B)	-	(8.52)	21.25	13.03
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD (A+B)	406.50	422.95	325.65	1,532.56
Paid up Equity Share Capital (Face value Re. 10 per share)	655.66	655.66	565.18	655.66
Other Equity	12,203.39	11,796.89	4,410.71	11,796.89
Earnings per equity share (Face value of Re. 10 each)				
Basic (in Rs.)	6.20	6.47	5.76	24.89
Diluted (in Rs.)	6.20	6.47	5.76	24.89

NOTES TO THE UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2024

1. The unaudited standalone financial results ('the Statement') of Jupiter Life Line Hospitals Limited ('the Company') for the quarter ended June 30, 2024 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on August 9, 2024. The Statement was subjected to limited review by the M/s. Aswin P. Malde & Co statutory auditor of the Company who have issued an unmodified limited review report.
2. The Statement has been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 'Interim Financial Reporting' specified under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other Generally Accepted Accounting Principles in India.
3. The Company's business activity primarily falls within a single reportable business segment and geographical segment namely 'Medical and Healthcare Services' and 'India' respectively. Hence, there are no additional disclosures to be provided under Ind-AS 108 – Segment information. The Company is not required to disclose separately segment reporting with regards to Hotel division as per Ind AS 108 because its Revenue, Profit & Loss and Assets are not exceeding 10% of Total Revenue, Profit & Loss and Assets of Company.
4. Figures for the quarter ended March 31, 2024 represents difference between the audited figures in respect of full financial year and the unaudited figure of nine months ended December 31, 2023.
5. Previous period figures have been regrouped / reclassified to conform the current period classification wherever required.
6. The aforesaid financial result is available on the company's website (www.jupiterhospital.com) and on the website of the Stock Exchanges (www.bseindia.com and www.nseindia.com).

For Jupiter Life Line Hospitals Limited

Dr Ankit A. Thakker
Whole Time Director and CEO

Place: Mumbai
Date : August 9, 2024

Independent Auditor's Review Report on consolidated unaudited quarterly financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

TO THE BOARD OF DIRECTORS OF JUPITER LIFE LINE HOSPITALS LIMITED

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of Jupiter Life Line Hospitals Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter ended 30th June 2024, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This statement which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") prescribed u/s 133 of the Companies Act 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:

Parent :

Jupiter Life Line Hospitals Limited

Subsidiaries :

Jupiter Hospital Projects Private Limited

Medulla Healthcare Private Limited

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditor referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial statements / financial information / financial results of 'Jupiter Hospital Projects Private Limited' one of the subsidiaries included in the consolidated unaudited financial results, whose interim financial statements / financial information / financial results reflect total assets of Rs.3164.49 million as at 30th June 2024 and total revenues of Rs. 478.48 million, total net profit after tax of Rs.39.56 million and total comprehensive income of Rs.39.56 million , for the quarter ended 30th June 2024, as considered in the consolidated unaudited financial results. These interim financial statements / financial information / financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditor and the procedures performed by us as stated in paragraph 3 above. Our conclusion on the Statement is not modified in respect of the above matters.

For Aswin P. Malde & Co.
Chartered Accountants
F.R.N. 100725W

Aswin P. Malde
Proprietor
M.No.032662
9th August, 2024, Mumbai
UDIN: 24032662BKAKAF5644

JUPITER LIFE LINE HOSPITALS LIMITED

CIN: U85100MH2002PLC137908

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2024

(Rs in Millions)

Particulars	Unaudited	Unaudited	Unaudited	Audited
	quarter ended	quarter ended	quarter ended	year ended
	30th June	31st March	30th June	31st March
	2024	2024	2023	2024
Revenue from Opertations	2,871.25	2,904.89	2,432.22	10,695.00
Other income	83.70	89.51	50.08	259.82
TOTAL INCOME	2,954.95	2,994.40	2,482.30	10,954.82
EXPENSES				
Purchases of Stock-in-Trade	535.53	533.62	441.07	1,918.09
Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	(33.33)	(5.80)	(17.03)	(23.41)
Employee benefits expense	512.66	514.64	451.08	1,899.36
Finance costs	10.77	9.25	121.60	263.41
Depreciation and amortisation expense	110.00	103.87	107.23	423.82
Professional Fees	722.20	717.16	619.36	2,713.58
Other expenses	495.68	522.49	407.78	1,805.82
TOTAL EXPENSES	2,353.51	2,395.23	2,131.09	9,000.67
Profit before exceptional items and tax	601.44	599.17	351.21	1,954.15
Exceptional items [net credit/ (charge)]	-	22.82	(13.60)	-
Profit before tax	601.44	621.99	337.61	1,954.15
Tax expenses	155.39	169.34	(202.36)	188.03
Current tax	145.91	159.27	102.08	518.87
Adjustments in respect of current income tax of previous year	-	3.27	-	1.52
MAT Credit Entitlement	-	-	-	-
Deferred tax credit/(charge)	9.48	6.80	(304.44)	(332.36)
PROFIT FOR THE PERIOD (A)	446.05	452.65	539.97	1,766.12
OTHER COMPREHENSIVE INCOME				
Items that will not be reclassified subsequently to profit or loss				
Remeasurements of the net defined benefit plans	-	(9.13)	-	(9.13)
Others	-	-	21.25	21.55
OTHER COMPREHENSIVE INCOME FOR THE PERIOD (B)	-	(9.13)	21.25	12.42
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD (A+B)	446.05	443.52	561.22	1,778.54
Paid up Equity Share Capital (Face value Re. 10 per share)	655.66	655.66	565.18	655.66
Other Equity	11,477.77	11,031.73	3,635.15	11,031.73
Earnings per equity share (Face value of Re. 10 each)				
Basic (in Rs.)	6.80	6.49	9.93	28.65
Diluted (in Rs.)	6.80	6.49	9.93	28.65

NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2024

1. The unaudited consolidated financial results (the Statement') of Jupiter Life Line Hospitals Limited ('JLHL' or 'the Company') along with its subsidiaries (collectively referred as 'the Group') for the quarter ended June 30, 2024 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on August 9, 2024. The Statement was subjected to limited review by the M/s. Aswin P. Malde & Co statutory auditor of the Company who have issued an unmodified limited review report.
2. As per the Companies Act, 2013 a – “subsidiary company” or “subsidiary”, in relation to any other company (that is to say the holding company), means a company in which the holding company—
 - (i) controls the composition of the Board of Directors; or
 - (ii) exercises or controls more than one-half of the total share capital either at its own or together with one or more of its subsidiary companies.

The entities considered in the limited review financial statements are listed below:

Name of the company	Country of Incorporation	Proportion of ownership interest
Jupiter Hospital Projects Private Limited	India	96.56%
Medulla Healthcare Private Limited	India	100.00%

In case of non-body corporate (partnership firms), consolidation is done on the net income basis [share of profit/(loss)], reflected in the head other income in consolidated statement of profit & loss

The non-body corporates which are considered on net income basis are listed below:

Name of the entity	Country of Incorporation	Proportion of ownership interest
Jupiter Pharmacy	India	95%
Katyayini Hospitality	India	95%

3. The Statement has been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 'Interim Financial Reporting' specified under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other Generally Accepted Accounting Principles in India.
4. The Group's business activity primarily falls within a single reportable business segment and geographical segment namely 'Medical and Healthcare Services' and 'India' respectively. Hence, there are no additional disclosures to be provided under Ind-AS 108 – Segment information. The Group is not required to disclose separately segment reporting with regards to Hotel division as per Ind AS 108 because its Revenue, Profit & Loss and Assets are not exceeding 10% of Total Revenue, Profit & Loss and Assets of Group.

5. Figures for the quarter ended March 31, 2024 represents difference between the audited figures in respect of full financial year and the unaudited figure of nine months ended December 31, 2023.
6. Previous period figures have been regrouped / reclassified to conform the current period classification wherever required.
7. The aforesaid financial result is available on the company's website (www.jupiterhospital.com) and on the website of the Stock Exchanges (www.bseindia.com and www.nseindia.com).

For Jupiter Life Line Hospitals Limited

Dr Ankit A. Thakker
Whole Time Director and CEO

Place: Mumbai
Date : August 9, 2024

Annexure – II

Information as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular

Sr. No.	Particulars	Information
1.	Name of the Auditor	M/s. Varma & Varma, Chartered Accountants
2.	Reason for change viz. appointment, re-appointment, resignation, removal, death. Cessation or otherwise	Appointment of M/s. Varma & Varma, Chartered Accountants, as the Internal Auditor.
3.	Date of appointment/ re-appointment/cessation	August 09, 2024
4.	Term of appointment/ re-appointment	For Financial Year 2024- 25.
5.	Brief profile	<p>M/s. Varma & Varma is a Chartered Accountant Firm registered with Institute of Chartered Accountants of India with ICAI. The firm was established in 1935 and is led by 33 partners. The audit firm has valid peer review certificate.</p> <p>The firm had empanelled with the Comptroller and Auditor General of India (CAG), the Reserve Bank of India (RBI), World Bank, Securities and Exchange Board of India (SEBI), Audit Bureau of Circulations (ABC) etc.</p> <p>The firm provides a range of services which include audit & assurance, tax representation & advisory services, incorporation & investment advisory services, Business consultancy and valuation services. The firm has significant experience in providing auditing, taxation & advisory services to Hospitals and Healthcare clients.</p>
6.	Disclosure of relationships between Directors	Not related to any Director or Key Managerial Personnel of the Company.

Information as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular

Sr. No.	Particulars	Information
1.	Name of the Director	Mr. Amar Manjrekar (DIN: 00463989)
2.	Reason for change viz. appointment, re-appointment, resignation, removal, death. Cessation or otherwise	Appointment of Mr. Amar Manjrekar as Additional Director in the capacity of Non-Executive Independent Director
3.	Date of appointment/ re-appointment/cessation	August 09, 2024
4.	Term of appointment/ re-appointment	For a period of 5 years effective from August 09, 2024 up to August 08, 2029, subject to the approval of the Members of the Company
5.	Brief profile	<p>Mr. Amar Manjrekar, Founder, Chairman, and Managing Director of Amar Builders, is a veteran of the construction and real estate industry. He has a 40 year experience in the industry and has led Amar Builders to great heights and success.</p> <p>His expertise in real estate, construction technology, and project management ensures projects meet optimal timelines and the highest global standards. Under his leadership, the firm's engineering capabilities have flourished, fostering technical excellence and continuous improvement. Grounded in strong values and ethics, Mr. Manjrekar has propelled Amar Builders to high levels of customer satisfaction.</p> <p>He actively participates in industry forums like MBVA and CREDAI, and extends his extensive experience to the broader real estate community.</p>
6.	Disclosure of relationships between Directors	Not related to any Director or Key Managerial Personnel of the Company.
7.	Confirmation as required under BSE circular Number LIST/COM/14/2018-19 and NSE circular no. NSE/CML/2018/24 dated June 20, 2018	Mr. Amar Manjrekar is not debarred from holding the office of Director by virtue of any SEBI Order or any other such authority.